As previously reported, Jefferies upgraded Kodiak Sciences (KOD) to Buy from Hold with a price target of $20, up from $6. With three positive Phase 3 studies with anti-VEGF tarcocimab the firm calls Kodiak “a major turnaround play.” A new near-term catalyst, with VEGF/IL-6 data in MESI inflammation coming soon, brings a “whole new angle of upside indications,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD: